Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

667P - Furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases

Date

07 Dec 2024

Session

Poster Display session

Presenters

Yongchang Zhang

Citation

Annals of Oncology (2024) 35 (suppl_4): S1632-S1678. 10.1016/annonc/annonc1698

Authors

Y. Zhang, L. Zeng, N. Yang, W. Jiang, Y. Xiong, Z. Wang, H. Yang, L. Liu, C. Zhou, F. Zeng

Author affiliations

  • Department Of Lung/gastrointestinal Oncology, Hunan Cancer Hospital, Xiangya School of Medicine, Central South University, 410013 - Changsha, Hunan/CN

Resources

This content is available to ESMO members and event participants.

Abstract 667P

Background

CNS metastases is associated with impaired quality of life and shortened survival. Furmonertinib is a third-generation EGFR TKI with wide therapeutic range and well-tolerated safety profile from 40mg to 240mg daily, which can achieve high exposure in the brain. In second or later line setting, furmonertinib 160mg has showed better outcomes in CNS metastases patients than 80mg. Thus a multicencer, open-label, single-arm phase II study was conducted to explore furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive NSCLC patients with CNS metastases.

Methods

Treatment naive metastatic EGFR mutation-positive NSCLC patients with stable CNS metastases were enrolled. EGFR exon 19 deletion and/or exon 21 L858R mutation were eligible. Regimen was furmonertinib 160mg p.o qd. Primary endpoint was PFS. Secondary endpoints were CNS PFS, ORR, DCR, CNS ORR, CNS DCR and safety.

Results

Between November 2022 and July 2024, 30 patients were enrolled. Median age was 57.5 years (range 33–75), female 60%, ECOG PS 1 83.3%, never smokers 63.3%, EGFR L858R 53.3%. At data cutoff (July 12 2024), median follow-up was 8.2 months, treatment is ongoing in 18 patients and the longest exposure was 19.8 months. Among the 30 patients who received study treatment, 26 of them had at least once tumor response evaluation. Median PFS or median CNS PFS was not reached. ORR was 84.6% (95%CI 65.1% to 95.6%). DCR was 100% (95%CI 86.8% to 100%). CNS ORR was 96.2% (95%CI 80.4% to 99.9%), including 5 CR (5/26, 19.2%). CNS DCR was 100% (95%CI 86.8% to 100%). Only 1 patient experienced grade 3 rash assessed as treatment related adverse event (TRAE), which resulted in dose interruption and dose reduction. No grade 4 or 5 TRAE was reported. No treatment discontinuation due to TRAE was reported.

Conclusions

Furmonertinib 160mg as first-line treatment showed clinically meaningful efficacy and well-tolerated safety profile for metastatic EGFR mutation-positive NSCLC patients with CNS metastases. This study is still ongoing and further analyses of longer-term outcomes will be evaluated, which may provide more evidence to support furmonertinib 160mg treatment is in favor of CNS metastases patients.

Clinical trial identification

NCT05379803.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Shanghai Allist Pharmaceuticals Co., Ltd, Shanghai, China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.